DeathClinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events: 1 or more serious adverse events regardless of type of storage of the vaccine Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events: 1 or more serious adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Systemic adverse events at · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in participants with adverse events ‐ systemic adverse eventsClinical… compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ injection site adverse events Clinical criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine probably leads to higher participants with adverse events ‐ injection site adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Dropouts Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Live zoster vaccine showed no clear difference in dropoutsClinical or laboratory criteria compared with placebo (moderate certainty).
1 finding from 1 review
Cumulative incidence of herpes zoster at least 3.2 years · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to lower cumulative incidence of herpes zoster at least 3.2 years compared with placebo (moderate certainty).
1 finding from 1 review
Participants with adverse events ‐ death Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Pain · acute non‐specific LBP
It is very uncertain whether exercise therapy changes pain compared with sham/placebo treatment (very low certainty).
1 finding from 1 review
Functional ability · acute non‐specific LBP
It is very uncertain whether exercise therapy changes functional status compared with sham/placebo treatment (very low certainty).
1 finding from 1 review
Perceived recovery · acute non‐specific LBP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · acute non‐specific LBP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (any cause during hospitalisation or · children with respiratory syncytial virus infection
It is very uncertain whether summary of findings table ‐ Immunoglobulins changes mortality (any cause during hospitalisation or compared with placebo (very low certainty).
1 finding from 1 review
Length of hospitalisation (days) · children with respiratory syncytial virus infection
1 finding from 1 review
Adverse events of any severity or seriousness · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Effect on later sexual function · symptomatic or early postmenopausal women1.
4 findings from 1 review
no estimate extracted
3 studies · 699 participants
Moderate
no estimate extracted
1 study · 883 participants
Very low
no estimate extracted
1 study · 215 participants
Very low
Show 1 more finding
Effect on later sexual function · Postmenopausal women
5 findings from 1 review
no estimate extracted
1 study · 272 participants
Very low
no estimate extracted
6 studies · 608 participants
Moderate
no estimate extracted
1 study · 104 participants
Very low
Show 2 more findings
Estrogen + progestogens · symptomatic or early postmenopausal women1.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ADHD symptoms · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes ADHD symptoms: all parallel‐group trials and first‐period cross‐over… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review